AxoGen, Inc. (AXGN) Stock Score, Valuation & Financial Research
AxoGen, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for AXGN
AxoGen, Inc. currently has a Wall Street Score of 28/100. The stored market price is $42.16. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What AxoGen, Inc. does
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding sof
AXGN financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $42.16
- Market capitalization:
- $2.27B
- Revenue:
- $251.2M
- Net income:
- $-33.5M
- Free cash flow:
- $-2.9M
- Cash:
- $94.6M
- Total debt:
- $20.1M
- EPS:
- -0.67
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 28/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-2.9M, showing cash burn in the current stored period.
- The balance sheet shows $94.6M of cash versus $20.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research AXGN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.